[go: up one dir, main page]

WO2004003167A3 - Gucy1b2 genetic markers for ldl cholesterol response to statin therapy - Google Patents

Gucy1b2 genetic markers for ldl cholesterol response to statin therapy Download PDF

Info

Publication number
WO2004003167A3
WO2004003167A3 PCT/US2003/020606 US0320606W WO2004003167A3 WO 2004003167 A3 WO2004003167 A3 WO 2004003167A3 US 0320606 W US0320606 W US 0320606W WO 2004003167 A3 WO2004003167 A3 WO 2004003167A3
Authority
WO
WIPO (PCT)
Prior art keywords
gucy1b2
genetic markers
ldl cholesterol
methods
response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/020606
Other languages
French (fr)
Other versions
WO2004003167A2 (en
Inventor
Bradley J Dain
Chad Messer
Carol R Reed
Ping Zhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cogenics Inc
Original Assignee
Genaissance Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genaissance Pharmaceuticals Inc filed Critical Genaissance Pharmaceuticals Inc
Priority to AU2003280285A priority Critical patent/AU2003280285A1/en
Publication of WO2004003167A2 publication Critical patent/WO2004003167A2/en
Anticipated expiration legal-status Critical
Publication of WO2004003167A3 publication Critical patent/WO2004003167A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Genetic markers in the GUCY1B2 gene associated with LDL cholesterol response to treatment with atorvastatin calcium are disclosed. Compositions and methods for detecting and using these GUCY1B2 genetic markers in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising a statin composition approved for treating patients having one of these GUCY1B2 haplotypes, methods and kits for predicting the response of an individual to a given statin treatment based on their haplotype profile, and methods for treating individuals with hyperlipidemia based on their haplotype profile.
PCT/US2003/020606 2002-06-28 2003-06-30 Gucy1b2 genetic markers for ldl cholesterol response to statin therapy Ceased WO2004003167A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003280285A AU2003280285A1 (en) 2002-06-28 2003-06-30 Gucy1b2 genetic markers for ldl cholesterol response to statin therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39281802P 2002-06-28 2002-06-28
US60/392,818 2002-06-28

Publications (2)

Publication Number Publication Date
WO2004003167A2 WO2004003167A2 (en) 2004-01-08
WO2004003167A3 true WO2004003167A3 (en) 2005-02-10

Family

ID=30000940

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020606 Ceased WO2004003167A2 (en) 2002-06-28 2003-06-30 Gucy1b2 genetic markers for ldl cholesterol response to statin therapy

Country Status (2)

Country Link
AU (1) AU2003280285A1 (en)
WO (1) WO2004003167A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269188A1 (en) * 2004-07-21 2008-10-30 Inserm Oatp-C Gene C463a Polymorphism Underlies Variable Response to Statin Therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AHREN, H.: "Biochemical, reagent kits offer scientists good return on investment", THE SCIENTIST, vol. 19, 24 July 1995 (1995-07-24), pages 20 - 24, XP002921157 *
BEHRENDS ET AL.: "The beta2 subunit of soluble guanylyl cyclase contains a human-specific frameshift and is expressed in gastric carcinoma", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 271, 2000, pages 64 - 69, XP001197340 *
DATABASE GENBANK, ON NCBI [online] XP002904285, Database accession no. (AF038499) *

Also Published As

Publication number Publication date
AU2003280285A8 (en) 2004-01-19
AU2003280285A1 (en) 2004-01-19
WO2004003167A2 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004048551A3 (en) Target for therapy of cognitive impairment
AU2003257110A1 (en) Polymorphisms for predicting disease and treatment outcome
WO2004113277A8 (en) Methods and compositions for treating amyloid-related diseases
WO2004011611A3 (en) Taci antibodies and uses thereof
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
AU2003233451A1 (en) Targets, methods, and reagents for diagnosis and treatment of schizophrenia
WO2008151803A3 (en) New polymorphisms in abcb1 associated with a lack of clinical response to medicaments
EP1765388B8 (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
WO2003060465A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of rheumatoid arthritis
AU2003223367A1 (en) Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2004033710A3 (en) Itgb3 gene haplotypes and atorvastatin dose effects on hdl cholesterol
WO2005059105A3 (en) Cdk5 genetic markers associated with galantamine response
WO2005019269A3 (en) Techniques and compositions for the diagnosis and treatment of cancer (muc1)
WO2005072151A3 (en) Apoe genetic markers associated with age of onset of alzheimer's disease
WO2004003167A3 (en) Gucy1b2 genetic markers for ldl cholesterol response to statin therapy
WO2004110365A3 (en) Liver related disease compositions and methods
WO2005042706A3 (en) Ephx2 genetic markers associated with galantamine response
AU2003258176A1 (en) Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2003091698A3 (en) Cetp genetic markers for statin-specific changes in hdl cholesterol
WO2006063703A8 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2005037204A3 (en) Ntrk1 genetic markers associated with age of onset of alzheimer's disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP